Abcam

Acquired by Danaher Corporation for $5.7 billion in 2023, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics.

Abcam President Markus Lusser. Courtesy – Abcam.

Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the company’s proprietary discovery platforms and antibody expertise. Its technologies are used by around 750,000 researchers globally.

Career opportunities at Abcam

Newsdesk

news@businessweekly.co.uk